Is Organon’s stock a good investment opportunity?
Apr 17, 2022 · Organon & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "OGN." Who are Organon & Co.'s major shareholders? Organon & Co.'s stock is owned by a variety of institutional and retail investors.
What is Organon?
Apr 21, 2022 · OGN | Complete Organon & Co. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
What is Organon&Co’s stock symbol?
May 05, 2022 · Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Who is the CEO of Organon Inc?
Real time Organon & Co. (OGN) stock price quote, stock graph, news & analysis.
Is Organon a good investment?
How many shares of Organon will Merck shareholders receive?
What kind of stock is Organon?
Will Organon be a publicly traded company?
Will Organon stock pay a dividend?
Does Merck own Organon shares?
What was value of Organon?
...
$ 34.62.
| Close | Chg | Chg % |
|---|---|---|
| $34.77 | -0.10 | -0.29% |
What is Organon a spinoff of?
What does spinoff mean?
Who bought Organon?
Is Organon & Co. a buy right now?
9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 5 ho...
When is Organon & Co.'s next earnings date?
Organon & Co. is scheduled to release its next quarterly earnings announcement on Monday, June 20th 2022. View our earnings forecast for Organon &...
How were Organon & Co.'s earnings last quarter?
Organon & Co. (NYSE:OGN) posted its earnings results on Wednesday, February, 16th. The company reported $1.37 EPS for the quarter, topping the Zack...
How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?
Organon & Co. declared a quarterly dividend on Friday, February 18th. Stockholders of record on Monday, February 28th will be given a dividend of $...
Is Organon & Co. a good dividend stock?
Organon & Co. pays an annual dividend of $1.12 per share and currently has a dividend yield of 3.13%. The dividend payout ratio of Organon & Co. is...
What guidance has Organon & Co. issued on next quarter's earnings?
Organon & Co. issued an update on its FY 2022 earnings guidance on Thursday, March, 10th. The company provided earnings per share guidance of for t...
What price target have analysts set for OGN?
9 analysts have issued twelve-month price objectives for Organon & Co.'s shares. Their forecasts range from $35.00 to $48.00. On average, they anti...
Who are Organon & Co.'s key executives?
Organon & Co.'s management team includes the following people: Mr. Kevin Ali , CEO & Director (Age 61) Mr. Matthew M. Walsh , Chief Financial O...
Who are some of Organon & Co.'s key competitors?
Some companies that are related to Organon & Co. include Astellas Pharma (ALPMY) , MERCK Kommanditgesellschaft auf Aktien (MKGAF) , Horizon Ther...
About Organon & Co
2.2 Analyst's Opinion
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Is Organon & Co. a buy right now?
Organon & Co. has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.
When is Organon & Co.'s next earnings date?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Organon & Co. stock.
How were Organon & Co.'s earnings last quarter?
Organon & Co. is scheduled to release its next quarterly earnings announcement on Monday, June 20th 2022. View our earnings forecast for Organon & Co..
How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?
Organon & Co. (NYSE:OGN) issued its earnings results on Wednesday, February, 16th. The company reported $1.37 earnings per share for the quarter, beating analysts' consensus estimates of $1.24 by $0.13. The company earned $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Organon & Co.
Is Organon & Co. a good dividend stock?
Organon & Co. announced a quarterly dividend on Friday, February 18th. Investors of record on Monday, February 28th will be paid a dividend of $0.28 per share on Thursday, March 17th. This represents a $1.12 annualized dividend and a yield of 3.11%.
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
Organon & Co. pays an annual dividend of $1.12 per share and currently has a dividend yield of 3.15%. View Organon & Co.'s dividend history.
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
JERSEY CITY, N.J.-- (BUSINESS WIRE)-- #Health--Organon reports results for the fourth quarter and full year ended December 31, 2021
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Organon (OGN) Could Beat Earnings Estimates Again
JERSEY CITY, N.J.-- (BUSINESS WIRE)-- #Health--Organon to report 4th Quarter and full year 2021 earnings
Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon's acquisition of Karolinska Development's portfolio company Forendo Pharma has been successfully completed
JERSEY CITY, N.J.-- (BUSINESS WIRE)-- #Health--Organon CEO and CFO to participate in JP Morgan Conference Fireside Chat
Organon Completes Acquisition of Forendo Pharma
STOCKHOLM SWEDEN – December 13, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the previously announced transaction, in which the global pharmaceutical company Organon & C...
Organon Stock Review: Business Overview
JERSEY CITY, N.J.-- (BUSINESS WIRE)-- #Endometriosis--Organon Announces Close of Forendo Pharma
Organon Stock Review: Why Share Price Is Depressed
Source: Merck Investor Day Featuring Organon & Co / Diversified portfolio and scaled organization
Organon Stock Review: Growth
As discussed earlier, Organon’s share price remains depressed since it started trading in the stock exchange.
Organon Stock Review: Filling The Gap
Organon projects its Established brands to stabilize and decline marginally in the long-term. On the other hand, management forecast low double-digit growth in its Women’s Health and Biosimilars operating segments.
Modest Debt Level
In the near term, we are likely to continue to see high double-digit growth in its Women’s Health and Biosimilars segments.
Organon Stock Review: Valuation
As of Q2 2021, cash and cash equivalents were US$730 million, debt was US$9.348 billion. Thus, net debt will come in at US$8.618 billion.
Conclusion
Source: Organon & Co Q2 2021 Financial Results / Condensed Consolidated Statement of Income
Organon & Co. (NYSE:OGN) Price Target and Consensus Rating
To sum up, Organon, the overlooked Merck spinoff, presents a compelling investment opportunity at the moment. With a potential for its share price to 2x from the current level moving forward.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Organon & Co. (NYSE:OGN) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
History
According to the issued ratings of 9 analysts in the last year, the consensus rating for Organon & Co. stock is Hold based on the current 5 hold ratings and 4 buy ratings for OGN. The average twelve-month price target for Organon & Co. is $39.88 with a high price target of $48.00 and a low price target of $35.00.
Products
Organon was founded by Dr. Saal van Zwanenberg in Oss, the Netherlands, in 1923 as a separate part of the meat factory Zwanenberg's fabrieken. Its first product was insulin in 1923. In the thirties it manufactured estrogens.
Research compounds
Products include: Esmirtazapine, Remeron, Remeron SolTab, Sustanon, Deca-Durabolin, Pregnyl, Implanon, NuvaRing, Marvelon, Desolett and a variety of other contraceptive products.
Medicaid fraud
During its period of independent operation, Organon developed a large number of compounds which were never adopted for medical use, but continue to be used for a variety of scientific research. Notable compounds include:
Organon, here for her health
In 2007, whistleblower lawsuits were filed against Organon in federal courts in Massachusetts and Texas. Organon was accused of selling its anti-depression medication Remeron at a discount to nursing home pharmacies (in order to encourage use), yet filing claims to Medicare for reimbursement at the full, undiscounted price.
Together, our goal is to deliver solutions for the healthcare issues that matter most to her, today and every day
Organon is a global healthcare company formed through a spinoff from Merck (known as MSD outside of the U.S. and Canada) with a mission to deliver impactful medicines and solutions for a healthier every day.
